Oxidative stress and depression in Parkinson’s disease

Trofimova S.A.; Lukina L.V.; Mikhailov V.A.; Dubinina E.E.

doi:https://doi.org/10.17116/jnevro2025125091131

Trofimova S.A.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0002-0337-8784

Lukina L.V.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0001-8500-7268

Mikhailov V.A.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0002-7700-2704

Dubinina E.E.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0003-1568-3994

Oxidative stress and depression in Parkinson’s disease

Authors:

Trofimova S.A., Lukina L.V., Mikhailov V.A., Dubinina E.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(9): 131‑138

DOI: 10.17116/jnevro2025125091131

Read: 459 times

Contact the author

Table of contents

To cite this article:

Trofimova SA, Lukina LV, Mikhailov VA, Dubinina EE. Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(9):131‑138. (In Russ.)
https://doi.org/10.17116/jnevro2025125091131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

OBJECTIVE

The aim of this study was to study the complex relationship between markers of oxidative stress and depression in patients diagnosed with Parkinson’s disease, with an emphasis on how various therapeutic interventions affect these biochemical parameters.

MATERIAL AND METHODS

The study included 60 participants (26 women and 34 men, average age 65.13±0.84 years) who received Fluvoxamine 100 mg/day as monotherapy (main group, n=30) or combination therapy (comparison group, n=30), including the antioxidant Cytoflavin and Fluvoxamine 100 mg/day. The control group consisted of 20 practically healthy elderly people. Using clinical, psychometric, and statistical research methods, the dynamics of depression symptoms and markers of oxidative stress in patients diagnosed with Parkinson’s disease were evaluated during a three-month course of treatment with Fluvoxamine and Cytoflavin.

RESULTS

During 3 months of therapy, the average score on the Hamilton depression scale in the main group decreased from 26.63±0.33 to7.22±0.5 points (p<0.01), in the comparison group from 26.51±0.29 to 12.18±1.1 points. According to the HADS scale, the average score in the main group decreased from 15.46±0.8 to 7.1±0.1 points (p<0.05), and in the comparison group from 15.14±0.8 to 9.7±1.2 points. After the therapy, all patients showed a significant slowdown in lipid peroxidation processes, an increase in the concentration of antioxidant enzymes, and a statistically significant (p<0.01) increase in the concentration of reduced glutathione, with a more significant improvement in the main group.

CONCLUSION

The results of a comparative analysis of the effectiveness of treatment of depression in patients with Parkinson’s disease showed that the use of a combination of Fluvoxamine and Cytoflavin provides a more pronounced therapeutic effect compared with Fluvoxamine monotherapy. These findings emphasize the need to integrate combined approaches into the development of new treatment strategies for depressive states based on a personalized assessment of the clinical picture of depressive disorder and biomarkers of oxidative stress.

Keywords:

Parkinson’s disease

depression

oxidative stress

antioxidants

antidepressants

cytoflavin

fluvoxamine

monotherapy

combination therapy

Authors:

Trofimova S.A.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0002-0337-8784

Lukina L.V.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0001-8500-7268

Mikhailov V.A.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0002-7700-2704

Dubinina E.E.

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

ORCID: 0000-0003-1568-3994

Received:

04.08.2025

Accepted:

03.09.2025

Close metadata

References:

Anderson G, Maes M. Neurodegeneration in Parkinson’s Disease: Interactions of Oxidative Stress, Tryptophan Catabolites and Depression with Mitochondria and Sirtuins. Mol Neurobiol. 2014;49(2):771-783. https://doi.org/10.1007/s12035-013-8554-z
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-1601. https://doi.org/10.1002/mds.26424
Goncharova ZA, Rabadanova EA, Gelpey MA. Non=motor symptoms of Parkinson’s disease, their structure and impact on the quality of patients’ life. Practical medicine. 2015;9(5):111-115. (In Russ.).
Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197-211. https://doi.org/10.1016/s0197-4580(02)00065-9
Zhukova IA, Zhukova NG, Alifirova VM, et al. Depression and other non=motor manifestations of Parkinson’s disease. Klin. med. 2017;95(5):419-424. (In Russ.). https://doi.org/10.18821/0023-2149-2017-95-5-419-424
Lavrova AV, Gretskaya NM, Bezuglov VV. Role of Oxidative Stress in the Etiology of Parkinson’s Disease: Advanced Therapeutic Products. Russ J Bioorg Chem. 2021;47:980-996. https://doi.org/10.1134/S1068162021050307
Parkinson J. An Essay on the Shaking Palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223-236. https://doi.org/10.1176/jnp.14.2.223
Khedr EM, Abdelrahman AA, Elserogy Y, et al. Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life. Egypt J Neurol Psychiatry Neurosurg. 2020;56:116. https://doi.org/10.1186/s41983-020-00253-5
Nassif DV, Pereira JS. Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics. 2018;18(2):143-150. https://doi.org/10.1111/psyg.12302
Levin OS, Artemyev DV, Bril EV, et al. Parkinson’s disease: modern approaches to diagnosis and treatment. Clinical medicine. 2017;1(1(102)):45-51. (In Russ.).
Zhukova NG, Matveeva MV, Kazantseva PE, et al. Sarcopenia as a non=motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):15-22. (In Russ.). https://doi.org/10.17116/jnevro202412409115
Fedorova NV, Mireckaja AV. Affektivnye rasstrojstva pri bolezni Parkinsona. Psihicheskie rasstrojstva v obshhej medicine. 2009;02:36-39. (In Russ.).
Starkstein SE, Brockman S. Depression in Parkinson’s disease. Mov Disord Clin Pract. 2017;4(4):470-477. https://doi.org/10.1002/mdc3.12507
Ivanov MV, Dubinina EE, Neznanov NG, et al. Oxidative Stress in Psychiatry and Neurology. SPb.: FGBU «Sankt-Peterburgskij nauchno-issledovatel’skij psikhonevrologicheskij institut im. V.M. Bekhtereva», 2016. (In Russ.).
Tregubova IA, Kosolapov VA, Spasov AA. Antioxidants: Current Status and Prospects. Uspekhi fiziologicheskikh nauk. 2012;43(1):75-94. (In Russ.).
Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell. Physiol. 2013;31(6):761-777. https://doi.org/10.1159/000350094
Dooneief G, et al. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Parkinsons Dis. 2015:305-307.
Kostyuk VA, Potapovich AI, Kovaleva ZV. Prostoi chuvstvitelnii metod dlya opredeleniya aktivnosti superoksiddismutazi, osnovannii na reaktsii okisleniya kvertitsina. Vopr med khimii. 1990;36:2:88-91. (In Russ.).
Vasenina EE, Levin OS. Oxidizing stress in patogeneza of neurodegenerate diseases: possibilities of therapy. Modern therapy in psychiatry and neurology. 2013;(3-4):39-46. (In Russ.).
Dolzhenko MN. Depressive and anxiety disorders in cardiology: the possibilities of combination therapy with an antidepressant and antihypoxant. Novosti meditsiny i farmatsii. 2013;14(465):10-12. (In Russ.).
Gavrilov VB, Gavrilov AR, Mazhul LM. Analiz metodov opredeleniya produktov perekisnogo okisleniya lipidov v sivorotke krovi po testu s tiobarbiturovoi kislotoi. Vopr med himii. 1987;1:118-122. (In Russ.).
Beutler E. Red cell metabolism. New York; London, 1975:89-90.
Chernishov VP. Opredelenie vosstanovlennogo i okislennogo glutationa v eritrotcitah beremennih zhenshin. Lab Delo. 1983;3:31-33. (In Russ.).
Hoehn MM, Yahr MD. Parkinsonism: Onset, Progression and Mortality. Neurology. 1967;17(5):427-442. https://doi.org/10.1212/WNL.17.5.427
Tretyakova EE, Masaleva IO. Depressive disorders in Parkinson’s disease, possibility of correction. International Research Journal. 2016;2(44). URL: [object Object]. Accessed date 13.04.2025. (In Russ.). https://doi.org/10.18454/IRJ.2016.44.013
Putilina MV, Teplova NV. Possible prospects for the combined administration of antidepressants and antioxidants in neurological patients. Medical Council. 2023;(21):80-87. (In Russ.). https://doi.org/10.21518/ms2023-376
Dubinina EE. The products of oxygen metabolism in the functional activity of cells (life and death, creation and destruction). Physiological and clinical-bio- chemical aspects. SPb.: Izdatel’stvo Meditsinskaya pressa. 2006.
Trofimova SA, Balunov OA, Dubinina EE. Perspectives of treatment of patients with ischemic stroke: the place and the role of cytoflavin. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(6):49-53. (In Russ.)
Eshhenko N.D. Biochemistry of mental and nervous diseases. Selected Sections: Study Guide SPb.: Izd-vo S.-Peterburgskogo un=ta. 2004. (In Russ.).
Goncharova ZA, Kolmakova TS, Oksenyuk OS, et al. Multi-parametric assessment of biochemical blood markers in Parkinson’s disease. Prakticheskaya medicina. 2018;10:87-91. (In Russ.). https://doi.org/10.32000/2072-1757-2018-10-87-91
Trofimova SA, Balunov OA, Dubinina EE. Oxidative stress and post-stress depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):44-49. (In Russ.). https://doi.org/10.17116/jnevro202012007144
Trofimova SA, Dubinina EE, Balunov OA, et al. The effect of medications that are used for the treatment of ischemic stroke consequences on the free radical oxidation in model system. Clin. Pharmacol. Ther. 2015;24(4):34-37. (In Russ.).
Lavrova AV, Gretskaya NM, Bezuglov VV. Role of Oxidative Stress in the Etiology of Parkinson’s Disease: Advanced Therapeutic Products. Russ J Bioorg Chem. 2021;47:980-996. https://doi.org/10.1134/S1068162021050307
Akhmadeeva GN, Magzhanov RV, Tayupova GN, et al. Anxiety and depressive disorders in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1-2):54-58. (In Russ.). https://doi.org/10.17116/jnevro20171171254-58
Nodel MR. Parkinson’s disease: focus on neuropsychiatric disorders. Russian Journal of Geriatric Medicine. 2020;3 205-211. (In Russ.). https://doi.org/10.37586/2686-8636-3-2020-205-211
Tregubova IA, Kosolapov VA, Spasov AA. Antioxidants: Current Status and Prospects. Uspekhi fiziologicheskikh nauk. 2012;43(1):75-94. (In Russ.).
Bakuleva NI, Zemskov AM, Liventseva DV, et al. Important Questions of Modern Approaches to Pharmacological Treatment of Anxiety and Depression: Combination of Antioxidant and Anti-Depressive Therapeutic Effects (Literature Review). Science of the young (Eruditio Juvenium). 2024;12(2):295-302. (In Russ.). https://doi.org/10.23888/HMJ2024122295-302